Algenomics Signs MOU with Rokit Healthcare for Regenerative Medicine and Anti-Aging Collaboration

Algenomics, a company specializing in the development of RNA-based gene therapies, announced on July 15 that it has signed a memorandum of understanding (MOU) with Rokit Healthcare and its subsidiary, Rokit Genomics, for joint research and business collaboration on a new anti-aging program.

Commemorative photo of the memorandum of understanding signing ceremony. Algenomics

The two parties have agreed to evaluate the potential for joint research and commercialization based on Algenomics' proprietary circular RNA platform technology and Rokit Healthcare and Rokit Genomics' regenerative medicine and anti-aging technologies. They also plan to pursue future collaboration for joint research and technology commercialization.

This agreement goes beyond simple research, encompassing a broad structure for cooperation that includes the acquisition of proof-of-concept data, business development, and technology transfer.

Algenomics possesses circular RNA platform technology that leaves no extraneous external sequences whatsoever and has secured fundamental patents in major countries worldwide, including the United States. In May of this year, the company participated in the American Society of Gene & Cell Therapy (ASGCT 2026), where it presented research results on in vivo immune cell delivery using circular RNA and polymer-based delivery systems. Algenomics has also been filing patents for optimization studies and evergreening strategies, including circular RNA structure engineering.

Rokit Healthcare, founded in 2012, is a regenerative medicine company that develops and commercializes a customized organ regeneration platform based on AI-enabled lesion recognition and modeling technology as well as disposable regenerative kits. Rokit Genomics, established in 2019, provides specialized bio-research services based on single-cell transcriptomics and gene analysis technologies. In particular, it offers essential genome analysis services for precision medicine and specialized bioinformatics analysis services.

Sungwook Lee, CEO of Algenomics, said, "By combining our advanced capabilities in regenerative bio research, we will expand the value of our circular RNA platform into the anti-aging and regenerative medicine markets."

This content was produced with the assistance of AI translation services.